Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
- Authors
- Oh, Tae Jung; Yu, Jae Myung; Min, Kyung Wan; Son, Hyun Shik; Lee, Moon Kyu; Yoon, Kun Ho; Song, Young Duk; Park, Joong Yeol; Jeong, In Kyung; Cha, Bong Soo; Kim, Yong Seong; Baik, Sei Hyun; Kim, In Joo; Kim, Doo Man; Kim, Sung Rae; Lee, Kwan Woo; Park, Jeong Hyung; Lee, In Kyu; Park, Tae Sun; Choi, Sung Hee; Park, Sung Woo
- Issue Date
- 6월-2019
- Publisher
- KOREAN DIABETES ASSOC
- Keywords
- Diabetes mellitus; type 2; Metformin; Voglibose
- Citation
- DIABETES & METABOLISM JOURNAL, v.43, no.3, pp.276 - 286
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- DIABETES & METABOLISM JOURNAL
- Volume
- 43
- Number
- 3
- Start Page
- 276
- End Page
- 286
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/65232
- DOI
- 10.4093/dmj.2018.0051
- ISSN
- 2233-6079
- Abstract
- Background: Combination of metformin to reduce the fasting plasma glucose level and an alpha-glucosidase inhibitor to decrease the postprandial glucose level is expected to generate a complementary effect. We compared the efficacy and safety of a fixed-dose combination of voglibose plus metformin (vogmet) with metformin monotherapy in drug-naive newly-diagnosed type 2 diabetes mellitus. Methods: A total of 187 eligible patients aged 20 to 70 years, with a glycosylated hemoglobin (HbA1c) level of 7.0% to 11.0%, were randomized into either vogmet or metformin treatments for 24 weeks. A change in the HbA1c level from baseline was measured at week 24. Results: The reduction in the levels of HbA1c was -1.62%+/- 0.07% in the vogmet group and -1.31%+/- 0.07% in the metformin group (P=0.003), and significantly more vogmet-treated patients achieved the target HbA1c levels of <6.5% (P=0.002) or <7% (P=0.039). Glycemic variability was also significantly improved with vogmet treatment, estimated by M-values (P=0.004). Gastrointestinal adverse events and hypoglycemia (%) were numerically lower in the vogmet-treated group. Moreover, a significant weight loss was observed with vogmet treatment compared with metformin (-1.63 kg vs. -0.86 kg, P=0.039). Conclusion: Vogmet is a safe antihyperglycemic agent that controls blood glucose level effectively, yields weight loss, and is superior to metformin in terms of various key glycemic parameters without increasing the risk of hypoglycemia.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.